Manual Instructions to Identify Patients Currently Receiving Treatment With Jaypirca for EHR Systems:

- Epic®
- iKnowMed®
- OncoEMR®
- Oracle Cerner®

There is an updated list of contracted specialty pharmacies for Jaypirca, with changes effective <November 6, 2025>. To ensure a smooth transition for existing patients, this guide was developed to assist in identifying patients who may be eligible for Jaypirca.

Indications

Jaypirca is indicated for the treatment of:

- Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
- Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in a confirmatory trial.

Select Important Safety Information

Infections: Fatal and serious infections (bacterial, viral, fungal) and opportunistic infections (including *Pneumocystis jirovecii* pneumonia and fungal infection) have occurred in Jaypirca-treated patients. Across clinical trials, Grade ≥3 infections occurred (25%), most commonly pneumonia (20%); fatal infections (5%), sepsis (6%), and febrile neutropenia (3.8%) occurred. In patients with CLL/SLL, Grade ≥3 infections occurred (32%), with fatal infections in 8%. Consider prophylaxis in patients at increased risk. Monitor for signs and symptoms of infection; based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Jaypirca®
pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

BTK=Bruton's tyrosine kinase; CLL=chronic lymphocytic leukemia; EHR=electronic health record; MCL=mantle cell lymphoma; R/R=relapsed or refractory; SLL=small lymphocytic lymphoma.

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Lilly
A MEDICINE COMPANY

Disclaimer:

- These instructions will identify patients currently receiving treatment with Jaypirca and their current pharmacy, as per the implementation instructions
- **It is important to note Jaypirca is only indicated for the treatment of adult patients with R/R CLL/SLL who have previously been treated with a covalent BTK inhibitor, and adult patients with R/R MCL after at least two lines of systemic therapy, including a BTK inhibitor**
- Eli Lilly and Company is not recommending use of Jaypirca inconsistent with product labeling
- Clinical decision-making is at the discretion of the prescriber
- While Lilly tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems, and Lilly shall have no liability thereto
- While EHRs may assist providers in identifying appropriate patients for consideration of assessment, treatment, and referral, the decision and action should ultimately be decided by a provider in consultation with the patient, after a review of the patient's records to determine eligibility, and Lilly shall have no liability thereto
- The instructions have not been designed to, and are not tools and/or solutions for, meeting Advancing Care Information and/or any other quality/accreditation requirement
-
- Capabilities, functionality, and setup (customization) for each EHR system may vary. Lilly shall not be responsible for revising the implementation instructions it provides to any Customer if the Customer modifies or changes its software or the configuration of its EHR system, after such time as the implementation instructions have been initially provided by Lilly
- The images shown are only to be interpreted as a guide to use the EHR system and are not an accurate representation of the EHR system

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

Contents

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

Background and Considerations

Effective <November 6, 2025>: Update to Contracted Specialty Pharmacies for Jaypirca

- Biologics and Onco360 Specialty Pharmacy are the contracted specialty pharmacies for Jaypirca
- The dispensing model for Jaypirca remains unchanged, with continued access through in-office and healthcare organization (HCO) pharmacies through Lilly's established inclusion criteria:
  - In-office pharmacies or practices
  - All pharmacies owned and operated by a hospital, cancer center, or health system
- To ensure a smooth transition for existing patients, this guide was developed to assist in identifying patients currently receiving treatment with Jaypirca

---

These instructions are specific to Jaypirca and to the specific EHR systems listed in the top navigation and are not appropriate for other conditions, treatments, or therapeutic areas, or for other EHR systems.

The process outlined hereafter is variable, and not all steps will apply to every health system. Any steps or settings hereafter that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. The practice is solely responsible for implementing, testing, monitoring, and the ongoing operation of any EHR tools.

This guide is not endorsed, certified, or sponsored by Epic, iKnowMed, OncoEMR, or Oracle Cerner. These EHR systems are not affiliated with Lilly's products and services.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

Epic Reporting Workbench Manual Instructions

Suggested Criteria

- Currently treated with Jaypirca

Reporting Workbench is a reporting tool, generally available to end users. The patient query uses one of the standard reporting templates to identify all patients. Consult your organization if additional user rights are required to access this functionality.

1. Access Reporting Workbench (click the Epic logo > Reports > My Reports)



2. Navigate to the Library tab from the Reports menu

3. Enter "Generic Criteria" or "Find Patients" in the search field and click Search

4. Select the Find Patients – Generic Criteria report and click New

5. The Report Settings field will display. Click the Criteria tab in the toolbar

6. Enter "Medications" in the search field (Filter Criteria)

7. Select the Meds: Current (by exact medication) criterion

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets
A Lilly Medicine

Epic Reporting Workbench Manual Instructions (continued)

8. Enter and select Jaypirca



9. Set the logic to include patients treated with Jaypirca



10. In the General tab, enter the desired Report Name (for example "Patients treated with Jaypirca") and a Description (for example "This patient query includes all patients treated with Jaypirca")



11. Select all desired display columns to include in the report

12. Click Save and Run to create the patient list. The list will display all patients matching the criteria. Use the filters to narrow down the patient list or export to Excel

13. Once exported to Excel, apply the filters in the column headings to stratify patients based on the number of matching criteria

Epic SlicerDicer Manual Instructions

Suggested Criteria

- Currently treated with Jaypirca

SlicerDicer is a reporting tool, generally available to end users. The patient query uses one of the standard data models to identify all patients. Consult your organization if additional user rights are required to access this functionality.

1. Access Slicer Dicer (click the Epic logo > Reports > SlicerDicer)

[Epic logo]



2. Select a desired data model. Available data models vary. Consider the Patients with Cancer (if available) or Patients data model for this patient query (the number in the data model box represent the base population and number of records in the data model)



Epic SlicerDicer Manual Instructions (continued)

3. In the right-hand column, select the desired patient base, for example All Patients (Note: First time users of SlicerDicer may see a tutorial prompted during initial use. Complete the tutorial and continue with the steps described in this resource)



4. In the Search for Criteria field, enter medication. Alternatively, the + Browse button can be used too. When using the + Browse button, a new screen will display where the filter criterion and inclusion/exclusion status can be selected
5. Select the Medications criteria
6. Enter the following medications to be included in the query:
   - Jaypirca (pirtobrutinib)

   This will be labeled as criterion 1 (see logic step 7)



7. Set the logic to include patients treated with Jaypirca



8. Click Save As to save the session. Click the last icon in the Visual Option section to see the query results. Refine the results as desired



9. Select the Share button in the menu toolbar

Epic SlicerDicer Manual Instructions (continued)

10. Enter a unique Name and Description, for example "Patients treated with Jaypirca"
11. In the Share With section, select the Specific People button. The report can be shared with Groups or Users as desired. Consider sharing the report with other specialists or peers if desired. Click Save and Share. The results can be exported to Excel if desired by right clicking the bar with the patient results and selecting *Show Slice in Reporting Workbench*



12. Once exported to Excel, apply the filters in the column headings to stratify patients based on the number of matching criteria



iKnowMed Manual Instructions

Suggested Criteria

- Currently treated with Jaypirca

Running a Pursuit List in iKnowMed requires a few steps. First, set the search criteria and run the query. If desired, the results of the query can be exported to Excel for further refinement.

1. Launch Practice Insights (may require access privileges)
2. Select Chart Explorer, then select Explorer



3. Add a Facet by clicking the plus (+) icon



4. Select the Medications Filter
5. Enter Jaypirca



6. Click the right arrow to drag all to the Selected Values window
7. Click Done
8. Click Explore to export the results to Excel for further manipulation



Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

iKnowMed Manual Instructions (continued)

Note: There are canned reports that could be leveraged in the User Dashboard. The Patient List Report can be used to find patients treated with Jaypirca.

Patient List:

1. Click User Dashboard > Library
2. Launch the Patient List reporting template



3. Click Create List to create a new list
4. Enter Jaypirca in the Medications filter
5. Click Search to launch the patient query (the list can be saved if desired)



6. Include all the patient's previous and current medications. When reviewing the patient's chart, confirm any prior and current systemic therapies
7. Export the reports to Excel by clicking Explore

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets
A Lilly Medicine

OncoEMR Manual Instructions

Suggested Criteria

- Currently treated with Jaypirca

Consider using OncoEMR's reporting functionality to identify patients. OncoEMR's Active Patient Drugs report template displays all patients with a medication ordered in a specific date range. Consult your organization if additional user rights are required to access this functionality.

1. Click General > Reports in the left navigation menu



2. Select the Active Patient Drugs Report



3. In the Start Date, set the desired starting date range point (for example when the practice started using the EHR)

4. In the End Date, set the desired end date range point (for example today's date)

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

OncoEMR Manual Instructions (continued)

5. In the Drug(s) field, enter Jaypirca

6. Once all criteria has been entered, run the report by clicking Run Now
7. The desired Report Outputs can be selected created. All results will display with additional information (for example Patient Name, MRN, Primary MD, Location/Preferred Clinic, Next Visit Date, Drug Found In Orders or eRx, Date, Drug name, Primary Diagnosis Code, Description, ...)
8. Export the data for further manipulation if desired. To export to excel, click the envelope icon and click Excel (.xlsx file)

eRX=electronic prescription; MD=medical doctor, MRN=medical record number.

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets
A Lilly Medicine

OracleCerner Manual Instructions

Suggested Criteria

- Currently treated with Jaypirca

Cerner's Discern Analytics 2 (DA2) is a reporting tool capable of creating patient queries. Consult your organization if additional user rights are required to access this functionality.

1. Launch Discern Analytics 2.0. It may be found as DA2.exe in the Cerner applications folder

2. Click the Domains tab to access available domains



3. Select File > New > Query or select the desired domain by double-clicking it



4. The query wizard will display available categories
5. In the Qualifications window, select the Order Synonym ID Filter and click Modify Filter List

OracleCerner Manual Instructions (continued)

6. Enter Jaypirca in the search field and select it from the results. Click Include



7. Select all the desired columns to include in the report by clicking the right arrow or dragging the selected folders to the Columns window

8. Select all desired display columns to include in the report

9. Set the general criteria for the report and enter a unique name (for example "Patients treated with Jaypirca")



10. Click Query > Query review or Run Query in Viewer in the Query tab to run the query

11. The results will display. The results may be further manipulated if desired or exported to Excel

12. Save the query

Please see Important Safety Information on pages 16-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

Important Safety Information for Jaypirca (pirtobrutinib)

Infections: Fatal and serious infections (including bacterial, viral, fungal) and opportunistic infections occurred in Jaypirca-treated patients. Across clinical trials, Grade ≥3 infections occurred (25%), most commonly pneumonia (20%); fatal infections (5%), sepsis (6%), and febrile neutropenia (3.8%) occurred. In patients with CLL/SLL, Grade ≥3 infections occurred (32%), with fatal infections occurring in 8%. Opportunistic infections included *Pneumocystis jirovecii* pneumonia and fungal infection. Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients at increased risk for infection, including opportunistic infections. Monitor for signs and symptoms, evaluate, and treat. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Hemorrhage: Fatal and serious hemorrhage has occurred with Jaypirca. Across clinical trials, major hemorrhage (Grade ≥3 bleeding or any central nervous system bleeding) occurred (2.6%), including gastrointestinal hemorrhage; fatal hemorrhage occurred (0.3%). Bleeding of any grade, excluding bruising and petechiae, occurred (16%). Major hemorrhage occurred when taking Jaypirca with (2.0%) and without (0.6%) antithrombotic agents. Consider risks/benefits of co-administering antithrombotic agents with Jaypirca. Monitor for signs of bleeding. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca. Consider withholding Jaypirca 3-7 days pre- and post-surgery based on surgery type and bleeding risk.

Cytopenias: Jaypirca can cause cytopenias, including neutropenia, thrombocytopenia, and anemia. Across clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (27%), decreased platelets (13%), and decreased hemoglobin (11%), developed. Grade 4 decreased neutrophils (15%) and Grade 4 decreased platelets (6%) developed. Monitor complete blood counts regularly. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Cardiac Arrhythmias: Cardiac arrhythmias occurred in patients taking Jaypirca. Across clinical trials, atrial fibrillation or flutter were reported in 3.4% of Jaypirca-treated patients, with Grade 3 or 4 atrial fibrillation or flutter in 1.6%. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred (0.4%). Cardiac risk factors such as hypertension or previous arrhythmias may increase risk. Monitor and manage signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea). Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Second Primary Malignancies: Across clinical trials, second primary malignancies, including non-skin carcinomas, developed in 9% of Jaypirca-treated patients, most frequently non-melanoma skin cancer (4.4%). Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor for development of second primary malignancies.

Hepatotoxicity, Including Drug-Induced Liver Injury (DILI): Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of DILI, has occurred in patients treated with BTK inhibitors, including Jaypirca. Evaluate bilirubin and transaminases at baseline and throughout Jaypirca treatment. For patients who develop abnormal liver tests after Jaypirca, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold Jaypirca. If DILI is confirmed, discontinue Jaypirca.

Please see Important Safety Information continued on pages 17-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

Important Safety Information for Jaypirca (pirtobrutinib) (continued)

Embryo-Fetal Toxicity: Jaypirca can cause fetal harm. Administration of pirtobrutinib to pregnant rats caused embryo-fetal toxicity, including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended 200 mg/day dose. Advise pregnant women of fetal risk and females of reproductive potential to use effective contraception during treatment and for one week after last dose.

Adverse Reactions (ARs) in Patients Who Received Jaypirca

The most common (≥30%) ARs in the pooled safety population of patients with hematologic malignancies (n=704) were decreased neutrophil count (54%), decreased hemoglobin (43%), decreased leukocytes (32%), fatigue (31%), decreased platelets (31%), decreased lymphocyte count (31%), calcium decreased (30%).

Mantle Cell Lymphoma

Serious ARs occurred in 38% of patients, with pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%) occurring in ≥2% of patients. **Fatal ARs** within 28 days of last dose occurred in 7% of patients, most commonly due to infections (4.7%), including COVID-19 (3.1% of all patients).

Dose Modifications and Discontinuations Due to ARs: Dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of Jaypirca in 9% of patients. Permanent discontinuation in >1% of patients included pneumonia.

Most common ARs (≥15%) and Select Laboratory Abnormalities (≥10%) (all Grades %; Grade 3-4 %): hemoglobin decreased (42; 9), platelet count decreased (39; 14), neutrophil count decreased (36; 16), lymphocyte count decreased (32; 15), creatinine increased (30; 1.6), fatigue (29; 1.6), musculoskeletal pain (27; 3.9), calcium decreased (19; 1.6), diarrhea (19; -), edema (18; 0.8), dyspnea (17; 2.3), AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included neutrophils decreased (10), platelets decreased (7), lymphocytes decreased (6).

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma from Single-Arm and Randomized Controlled Clinical Trials

Serious ARs occurred in 47-56% of patients across clinical trials. Serious ARs in ≥5% of patients in the single-arm trial were pneumonia (18%), COVID-19 (9%), sepsis (7%), febrile neutropenia (7%). Serious ARs in ≥3% of patients in the randomized controlled trial were pneumonia (21%), COVID-19 (5%), sepsis (3.4%). **Fatal ARs** within 28-30 days of last Jaypirca dose occurred in 8-11% of patients, most commonly due to infections (7- 10%), including sepsis (5%), COVID-19 (2.7-5%), and pneumonia (3.4%).

Dose Modifications and Discontinuations Due to ARs: Dose reductions in 3.6-10%, treatment interruption in 42-51%, and permanent discontinuation of Jaypirca in 9-17% of patients. Permanent discontinuation in >1% of patients included second primary malignancy, pneumonia, COVID-19, neutropenia, sepsis, anemia, and cardiac arrythmias.

Please see Important Safety Information continued on pages 18-19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets

A Lilly Medicine

Important Safety Information for Jaypirca (pirtobrutinib) (continued)

Adverse Reactions (ARs) in Patients Who Received Jaypirca (continued)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma from Single-Arm and Randomized Controlled Clinical Trials (continued)

Most common ARs and Select Laboratory Abnormalities (≥20%) (all Grades %; Grade 3-4 %)--in a randomized controlled trial: neutrophil count decreased (54; 26), hemoglobin decreased (45; 10), platelet count decreased (37; 17), pneumonia (28; 16), ALT increased (25; 1.8), creatinine increased (25; -), calcium decreased (23; 0.9), sodium decreased (22; 0.9), bilirubin increased (21; 0.9), upper respiratory tract infections (21; 0.9); **in a single-arm trial:** neutrophil count decreased (63; 45), hemoglobin decreased (48; 19), calcium decreased (40; 2.8), fatigue (36; 2.7), bruising (36; -), cough (33; -), musculoskeletal pain (32; 0.9), platelet count decreased (30; 15), sodium decreased (30; -), COVID-19 (28; 7), pneumonia (27; 16), diarrhea (26; -), abdominal pain (25; 2.7), lymphocyte count decreased (23; 8), ALT increased (23; 2.8), AST increased (23; 1.9), creatinine increased (23; -), dyspnea (22; 2.7), hemorrhage (22; 2.7), lipase increased (21; 7), alkaline phosphatase increased (21; -), edema (21; -), nausea (21; -), pyrexia (20; 2.7), headache (20; 0.9). Grade 4 laboratory abnormalities in >5% of patients included neutrophils decreased (23).

Drug Interactions

Strong CYP3A Inhibitors: Concomitant use increased pirtobrutinib systemic exposure, which may increase risk of Jaypirca ARs. Avoid using strong CYP3A inhibitors with Jaypirca. If concomitant use is unavoidable, reduce Jaypirca dose according to approved labeling.

Strong or Moderate CYP3A Inducers: Concomitant use decreased pirtobrutinib systemic exposure, which may reduce Jaypirca efficacy. Avoid using Jaypirca with strong or moderate CYP3A inducers. If concomitant use with moderate CYP3A inducers is unavoidable, increase Jaypirca dose according to approved labeling.

Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: Use with Jaypirca increased their plasma concentrations, which may increase risk of ARs related to these substrates for drugs sensitive to minimal concentration changes. Follow recommendations for these sensitive substrates in their approved labeling.

Please see Important Safety Information continued on page 19 and click for Prescribing Information and Patient Information for Jaypirca.

Jaypirca® pirtobrutinib 50, 100 mg tablets
A Lilly Medicine

Important Safety Information for Jaypirca (pirtobrutinib) (continued)

Use in Specific Populations

Pregnancy and Lactation: Due to potential for Jaypirca to cause fetal harm, verify pregnancy status in females of reproductive potential prior to starting Jaypirca. Presence of pirtobrutinib in human milk is unknown. Advise women to use effective contraception and to not breastfeed while taking Jaypirca and for one week after last dose.

Geriatric Use: In the pooled safety population of patients with hematologic malignancies, patients aged ≥65 years experienced higher rates of Grade ≥3 ARs and serious ARs compared to patients <65 years of age.

Renal Impairment: Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.

PT HCP ISI MCL_CLL Q42025

Please see Prescribing Information and Patient Information for Jaypirca.

Reference: Jaypirca. Prescribing Information. Lilly USA, LLC.

PP-PT-US-1486 11/2025

Jaypirca® pirtobrutinib 50, 100 mg tablets
A Lilly Medicine

Lilly
A MEDICINE COMPANY